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Background/Aims: Signal transducers and activators of 
transcription (STATs) are a family of transcription factors 
that are activated in response to cytokines and growth fac-
tors. STAT3 activation has been implicated in modulating 
the activity of downstream mediators, such as Bcl-xL and 
matrix metalloproteinase-2 (MMP-2). The aim of this study 
was to investigate the immunohistochemical expression 
of STAT3, B-cell lymphoma-extra large (Bcl-xL), and MMP-2 
proteins according to histopathological parameters in colon 
adenocarcinomas, including lymph node metastasis, tumor 
differentiation, the TNM stage and the tumor size. Methods: 
Immunohistochemical staining with monoclonal STAT3, 
Bcl-xL, and MMP-2 antibodies was performed on paraffin-
embedded specimens from 20 colon adenomas and 39 
adenocarcinomas. Results: The expression of STAT3, Bcl-xL, 
and MMP-2 was increased in the adenocarcinomas as com-
pared with the adenomas (p<0.001). STAT3 expression was 
stronger in tumors with a distant metastasis than in tumors 
without a distant metastasis (p=0.012). A larger tumor size 
was related to an increase in STAT3 expression (p=0.035). 
Conclusions: STAT3, Bcl-xL, and MMP-2 may play important 
roles in the tumorigenesis of colorectal carcinoma. STAT3 
may be indicative of a poor prognosis due to its correlation 
with distant metastases and a larger tumor size. (Gut Liver 
2012;6:45-51)
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INTRODUCTION
Colorectal cancer is the third most common malignancy and 
the incidence of colorectal cancer is high in Western countries.
1
The theory of adenoma-carcinoma sequence is now accepted 
as the mechanism of colorectal cancer.
2 While many of the 
oncogenes and tumor suppressor genes that are involved in 
the tumorigenesis of colorectal cancer have been identified, the 
molecular mechanisms of colorectal carcinoma are still poorly 
understood. With the description of the signal transduction 
cascades, it has recently become clear that the signal transduc-
ers and activators of transcription (STATs) signaling pathway 
may play an important role in the malignant transformation 
of human malignancies.
3 Signal transducer and activator of 
transcription 3 (STAT3) is a member of the STAT family and 
these proteins are transcription factors in the cytoplasm and 
important mediators of cytokines and growth factors.
4 Seven 
STATs have currently been identified in mammals and STAT3 is 
located on chromosome 17.
5
Recent studies have demonstrated the essential roles of STATs 
proteins in modulating the process of cell proliferation, differ-
entiation, and apoptosis.
6-8 There have been some studies show-
ing that the activation of STAT3 contributed to the process of 
apoptosis in ovarian cancer cells by regulating the expression 
of B-cell lymphoma-extra large (Bcl-xL),
9 and activated STAT3 
regulates the tumor invasion of melanoma cells by regulating 
the gene transcription of matrix metalloproteinase-2 (MMP-2).
10
Bcl-xL is a member of the Bcl-2 family protein first identified 
by Boise et al.
14 This protein is known to be an important factor 
that regulates apoptosis.
12 As a mitochondrial membrane pro-
tein, it prolongs the survival of cells by modulating the electri-46  Gut and Liver, Vol. 6, No. 1, January 2012
cal and osmotic homeostasis of the mitochondria in response to 
various stimuli.
13,14 
As a family of zinc-dependent endopeptidases, MMPs can 
degrade most of the components of the basement membrane 
and the extracellular matrix (ECM).
15 MMP-2 is a 72 kDa type 
IV collagenase and it is also known as gelatinase A. The role 
of MMP-2 in colorectal cancer was suggested for the first time 
in 1992 and it is known to participate in the destruction of the 
basement membrane at the early stage of colorectal cancer.
16,17
We investigated the expressions of STAT3, Bcl-xL, and MMP-
2 in colorectal adenoma and adenocarcinoma by performing 
immunohistochemistry and we evaluated the relationship be-
tween these proteins and the clinicopathologic parameters. 
MATERIALS AND METHODS 
1. Materials
We studied 20 cases of colorectal adenomas and 39 cases of 
primary human colorectal adenocarcinomas that were obtained 
from patients who had undergone endoscopic resection or sur-
gery at Daejeon St. Mary’s Hospital. There were 14 men and 6 
women in the adenoma group and 17 men and 22 women in 
the adenocarcinoma group. The median age of the adenoma 
group and the adenocarcinoma group was 56 and 70 years, re-
spectively. The colorectal adenomas were divided into low grade 
dysplasia and high grade dysplasia according to the World 
Health Organization (WHO) classification.
18 There were 10 low 
grade dysplasias and 10 high grade dysplasias in the adenoma 
group. We classified the stage of the adenocarcinomas accord-
ing to the tumor, node, metastasis (TNM) staging system of the 
American Joint Committee on Cancer,
19 and we assigned a his-
tological type according to the WHO classification as follows: 
well differentiated adenocarcinoma, moderately differentiated 
adenocarcinoma, and poorly differentiated adenocarcinoma.
18 
We summarized the basic demographic characteristics of the 
adenocarcinoma patients in Table 1. 
2. Methods
1) Immunohistochemical staining
The formalin fixed, paraffin embedded tissues were cut into 4 
μm sections and they were mounted onto poly-L-lysine coated 
glass slides. The sections were deparaffinized in xylene and, 
rehydrated in a graded series of alcohol solutions. These sec-
tions were then subjected to an antigen retrieval procedure; the 
slides were soaked in citrate buffer (10 mM, pH 6.0), heated for 
10 minutes twice (for 20 minutes overall) at 60
oC in an oven, 
washed in phosphate buffered saline (PBS) 3 times and then 
treated with 3% H2O2 solution for 10 minutes. 
We used the EnVision-HRP detection system (DAKO, Carpin-
teria, CA, USA) and the primary antibodies were anti-STAT3 
(dilution 1:100; Cell Signaling Technology, Beverly, MA, USA), 
anti-Bcl-xL (dilution 1:300; Cell Signaling Technology), and 
anti-MMP-2 (dilution 1:100; Abcam, Cambridge, MA, USA). The 
primary antibody was incubated with the slides for 60 minutes 
at room temperature. The slides were washed with PBS and re-
acted with EnVision reagent for 10 minutes and then they were 
stained with diaminobenzidine. The slides were counterstained 
with 10% Meyer’s hematoxylin and then they were observed 
using an optical microscope. Incubation without the primary 
antibody was used as a negative control. 
2) Analysis of the immunohistochemical staining
The immunoreactivity of STAT3, Bcl-xL, and MMP-2 pro-
teins was classified as follows: negative (-); weak staining (1+): 
≤25% of the cells staining positive; moderate staining (2+): 25% 
to 50% of the cells staining positive and strong staining (3+): 
Table 1. The Basic Characteristics and Clinicopathologic Parameters 




Gender Male 17 (43.6)
Female 22 (56.4)
Age, yr Range 36-89
Mean 66.6
Median 70




Lymph node involvement N0 17 (43.6)
N1 22 (56.4)
Distant metastasis M0 28 (71.8)
M1 11 (28.2)




Histologic grade Well differentiated 6 (15.4)
Moderately differentiated 28 (71.8)
Poorly differentiated 5 (12.8)
Tumor size ≥5 cm 16 (41)
<5 cm 23 (59)
Primary site  Right colon 13 (33)
Left colon 10 (26)
Rectum 16 (41)
T1, tumor invades the submucosa; T2, tumor invades the muscularis 
propria; T3, tumor invades through the muscularis propria into the 
subserosa or perirectal tissues; T4, tumor directly invades other or-
gans or structures and/or perforates the visceral peritoneum; N0, no 
regional lymph node metastasis; N1, lymph node metastasis; M0, no 
distant metastasis; M1, distant metastasis; TNM, tumor, node, metasta-
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>50% of the cells staining positive. Each observer estimated the 
percentage of cells stained and they graded the intensity of im-
munostaining based on a visual assessment of the intensity of the 
brown reaction product within the cell cytoplasm. The final immu-
nostaining score reported was the average of two observers.
3) Statistical analysis
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) was used for 
the statistical analyses. The analyses that compared the expres-
sions of STAT3, Bcl-xL, and MMP-2 between adenoma and 
adenocarcinoma were performed using independent t-tests. The 
data are presented as means±standard deviations. The relation-
ships between the levels of STAT3, Bcl-xL, and MMP-2 and the 
various clinicopathological parameters in adenocarcinoma were 
determined by chi-square tests. p-values <0.05 were considered 
statistically significant. 
Table 2. The Staining Intensity of STAT3, Bcl-xL, and MMP-2 in Colon Adenoma and Adenocarcinoma  
STAT3 Bcl-xL MMP-2
No. (%) Intensity No. (%) Intensity No. (%) Intensity
Adenoma (n=20) 18 (90) 1.45±0.75 18 (90) 1.5±0.76   9 (45) 0.5±0.6
Low grade (n=10) 1.7±0.67 1.2±0.63 0.4±0.51
High grade (n=10) 1.2±0.79 1.8±0.78 0.6±0.69
Adenocarcinoma (n=39) 38 (97) 1.92±0.74* 38 (97)  2.3±0.78* 34 (87) 1.7±0.92*
Data are presented as mean±SD or number (%).
STAT3, signal transducer and activator of transcription 3; Bcl-xL, B-cell lymphoma-extra large; MMP-2, matrix metalloproteinase-2.
*p-value<0.05 compared to the adenoma.
Fig. 1. Immunohistochemical staining for STAT3 in colon adenoma and adenocarcinoma. (A) Normal tissue (×100, negative). (B) Adenoma (×100, 
weakly positive). (C) Adenocarcinoma (×100, moderately positive). (D) Adenocarcinoma (×100, strongly positive).48  Gut and Liver, Vol. 6, No. 1, January 2012
RESULTS
1. The expressions of STAT3, Bcl-xL, and MMP-2 in colorec-
tal adenoma
The expression of STAT3, Bcl-xL, and MMP-2 was seen in 
90% (18/20), 90% (18/20), and 45% (9/20) of the colorectal 
adenoma, respectively. The staining intensity of STAT3, Bcl-xL, 
and MMP-2 was 1.45±0.75, 1.5±0.75, and 0.5±0.6, respectively. 
When the staining intensity between low grade dysplasia and 
high grade dysplasia was compared, there was no statistically 
significant difference (Table 2).
2. The expressions of STAT3, Bcl-xL, and MMP-2 in colorec-
tal adenocarcinoma
The expression of STAT3, Bcl-xL, and MMP-2 was seen in 
97%, 97%, and 87%, respectively, of the colorectal adenocar-
cinomas. The staining intensity of STAT3, Bcl-xL, and MMP-2 
was 1.92±0.74, 2.3±0.78, and 1.7±0.92, respectively. The stain-
ing intensity of STAT3, Bcl-xL, and MMP-2 was significantly 
higher in the colorectal adenocarcinoma as compared with that 
of the adenoma respectively (p<0.001) (Fig. 1, Table 2). 
The status of the STAT3 expression in colorectal adenocar-
cinoma is summarized in Table 3. The STAT3 expression was 
stronger in the colorectal adenocarcinoma with distant metas-
tasis than that in the colorectal adenocarcinoma without distant 
metastasis (p=0.012), and it was also stronger in the larger size 
tumor (≥5 cm) than that in the smaller size tumor (p=0.035). 
We classified the adenocarcinoma group according to the 
histologic grade as well, moderate and poorly differentiated. The 
expression of STAT3 was stronger in the differentiated group of 
tumors (well and moderate differentiated adenocarcinoma) than 
that in the poorly differentiated group (p=0.031). The expres-
sions of Bcl-xL and MMP-2 were also stronger in the differenti-
ated group (well and moderate differentiated adenocarcinoma) 
than that in the poorly differentiated group (p=0.034, p=0.01, 
respectively, the data is not shown). The expression of each pro-
tein was not significantly different according to age, gender, the 
TNM staging and the lymph node status. 
DISCUSSION 
STAT3 is a member of the Janus activated kinase (JAK)/STAT 
signaling pathway and it was first identified as a DNA binding 
factor that selectively binds to the interleukin-6 (IL-6)-responsive 
element in the promoter of acute phase genes from IL-6 stimu-
lated hepatocytes.
6,20 STAT3 is activated by many cytokines and 
growth factors, including epidermal growth factor, platelet-
derived growth factor and IL-6 as well as by oncogenic proteins, 
such as Src and Ras.
6,21
The biologic functions of STAT3 are very broad. STAT3 plays 
a crucial role in the regulation of cell proliferation, survival, 
apoptosis, and differentiation. Constitutively activated STAT 
proteins have been observed in a wide variety of human cell 
lines and primary tumors including leukemia, multiple myelo-
ma, breast cancer, prostate cancer, and other cancers.
22-25
In this study, we found that the STAT3 expression was signif-
icantly higher in the tumors with distant metastasis and a larger 
size. The staining intensity of STAT3 was significantly higher 
in the adenocarcinomas than that in the adenomas. Ma et al.
26 
reported that there was a significant correlation between the 
expression of the phosphorylated or activated form of STAT3 
(p-STAT3) and the presence of lymph node metastasis and inva-
sion in human colorectal carcinoma. Although Kusaba et al.
27 
reported on the correlation between p-STAT3 and lymph node 
metastasis or the Duke stage, there was no significant correla-
tion of STAT3 with lymph node metastasis and the TNM stage 
in our current study. 
Although tyrosine phosphorylation is required for STAT3 to 
bind to specific DNA target sites, the nuclear import of STAT3 
Table 3. The Relationship between Clinicopathologic Parameters and 


















  ≥70 0 3 10 7
  <70 1 6 11 1
Gender 0.415
  Male 1 5 7 4
  Female 0 4 14 4
Stage 0.556
  I+II 0 3 10 2
  III+IV 1 6 11 6
Lymph node involvement 0.465
  Negative 0 4 11 2
  Positive 1 5 10 6
Distant metastasis 0.012*
  M1 1 3 2 5
  M0 0 6 19 3
Histologic grade 0.031*
  Well 0 0 6 0
  Moderate 0 7 14 7
  Poor 1 2 1 1
Size 0.035*
  ≥5 cm 0 0 6 5
  <5 cm 1 9 15 3
STAT3, signal transducer and activator of transcription 3; M0, no distant 
metastasis; M1, distant metastasis. 
*p-value<0.05.Lee SW, et al: Expression of STAT3, Bcl-xL, and MMP-2 in Colon  49
takes place constitutively and independently of tyrosine phos-
phorylation
28 and phosphorylation is not a prerequisite for 
STAT3 nuclear import. Thus, the requirement of phosphoryla-




32 reported that STAT3 upregulated the expression of 
MMP-2, and that this was correlated with metastasis and inva-
sion of carcinoma. Horiguchi et al.
33 reported that the activa-
tion of STAT3 in renal cell carcinoma is associated with distant 
metastatic disease and the roles and mechanisms of activated 
STAT3 in metastases have been discovered.
21
Numerous downstream genes of STAT3 signaling have been 
identified. p-STAT3 has been shown to protect tumor cells from 
apoptosis and promote cell proliferation by regulating the genes 
encoding antiapoptotic associated proteins and proliferation as-
sociated proteins such as Bcl-xL and cyclin D1.
21,31
Since the discovery of Bcl-2, several homologs of this gene 
and its encoded protein have been identified. Some of these ho-
mologs function as blockers of cell death (Bcl-2, Mcl-1, Bcl-xL), 
whereas others are promoters of apoptosis (Bax, Bak, Bcl-xS).
34 
Two distinct forms of Bcl-x (Bcl-xL, Bcl-xS) have been identi-
fied and they have different functions and molecular weights. 
Bcl-xL is a 21-kD protein and it suppresses apoptosis, whereas 
Bcl-xS is 19-kD and it promotes apoptosis.
11,35 Studies of Bcl-
xL protein in gastric, colorectal and pancreatic cancers have 
been reported. The expression rate of Bcl-xL was related with 
the prognosis of patients with pancreatic cancer and Bcl-xL was 
increased in colorectal cancer.
26,36-38
In this study, the expression of Bcl-xL was more increased in 
adenocarcinoma than that in adenoma, with significance. Zhang 
et al.
39 reported that the expression of Bcl-xL was associated 
with lymph node metastasis, the pathologic grade and Duke’s 
stage of colorectal carcinoma. Krajewska et al.
37 suggested that 
the expression of Bcl-xL was increased in undifferentiated pri-
mary colorectal cancers. Kusaba et al.
40 reported that there was 
no significant correlation between p-STAT3 immunoreactivity 
and the differentiation of colorectal adenocarcinomas.
Our result showed a decreased expression of STAT3, Bcl-xL, 
and MMP-2 in undifferentiated adenocarcinoma. However, our 
results have limitations due to the small number of subjects. 
Therefore, further studies are needed to identify the relationship 
between these proteins and the differentiation of adenocarci-
noma. 
There is substantial evidence of STAT3’s involvement in 
tumor cell migration and invasion. STAT3 has been shown to 
transcriptionally activate the expression of genes that promote 
tumor cell migration and invasion. Specifically, activated STAT3 
regulates tumor invasion of melanoma cells by regulating the 
gene transcription of MMP-2.
32 The MMP family consist of 
roughly 20 members, and they are chiefly involved in the dis-
semination of cancer cells by breaking down the ECM and cre-
ating an environment that supports the initiation and mainte-
nance of tumor growth.
41 There have been several recent reports 
that the expression of MMP-2 protein was increased according 
to the depth of invasion and it was increased in adenocarci-
noma rather than in adenoma.
42,43 Shin et al.
44 reported that the 
expression of MMP-2 is correlated with lymph node metastasis 
in colorectal cancer.
In this study, the MMP-2 expression was significantly higher 
in the adenocarcinomas than that in the adenomas, and the cor-
relation with lymph node metastasis and the pathologic stage 
was not shown. It is known that the MMP-2 protein expression 
is related with the distant metastatic process.
45 In this study, the 
MMP-2 expression was not related with distant metastasis. 
Our results suggested that the expressions of STAT3, Bcl-xL, 
and MMP-2 were increased in both adenoma and adenocarci-
noma as compared with the expressions in the normal mucosa, 
and the staining intensity was increased with the progression 
from adenoma to adenocarcinoma. The results showed that 
these proteins may be related to the development of colorectal 
adenocarcinoma with the progression from adenoma to carci-
noma. Especially, our results showed that STAT3 had correla-
tion with distant metastasis and a larger tumor size in colorectal 
adenocarcinoma, so we suggest that STAT3 might be related 
with a poor prognosis for patients with colorectal adenocarci-
noma. However, further studies are needed for understanding 
the detailed relationships of these proteins in colorectal carcino-
genesis. 
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